FDA Output
FDA Output, September 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in September 2026. Updated September 14.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
The Brief
As Dollars Chase AI Dream, Investors Stay Grounded
Despite geopolitical challenges and fierce competition for capital, the medtech investment market has maintained the momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways Pick of the Week: UK Eyes Centralized Licensing
UK floats legislation that could lead to direct MHRA device reviews. Excerpted from Pathways Picks September 2: UK Eyes Centralized Licensing, FDA-SEC Pact, and More.